Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

Tiziana Life Sciences ( ($TLSA) ) has shared an update. On February 25, 2025, Tiziana Life Sciences announced the nearing completion of a ...

Alzheimer’s disease remains one of the most pressing medical mysteries of our time. Despite decades of research, scientists are still uncovering the complex mechanisms behind this ... Continue Reading ...

Tiziana Life Sciences (TLSA) announced that a nasal anti-CD3 preclinical study is nearing completion, and that foralumab could offer a novel ...

NEW YORK, Feb. 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hum ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Ivor Elrifi, CEO of Tiziana Life Sciences, commented, “Partnering with Renaissance is a significant milestone in our mission to bring intranasal foralumab to patients in need. Their proven track ...